LL-37 (CAP-18)

LL-37 (CAP-18) Peptide Vials

Introduction

LL-37 (CAP-18) Vials represent a cutting-edge research product designed exclusively for scientific investigations. These vials contain LL-37, a naturally occurring antimicrobial peptide recognized for its diverse applications in various research domains.

Key Characteristics

LL-37 (CAP-18) Vials feature a concentrated and purified form of LL-37, ensuring high-quality and reproducibility in research settings. The vials are carefully prepared to meet the stringent standards required for scientific investigations.

Research Applications

These vials find applications in a range of research studies, spanning immunology, microbiology, and inflammatory disorders. The versatility of LL-37 makes it an invaluable tool for exploring various biological processes.

Research Benefits

LL-37 and Rheumatoid Arthritis

Numerous studies suggest a potential link between LL-37 and rheumatoid arthritis. The peptide’s anti-inflammatory properties may contribute to modulating immune responses, offering a promising avenue for research into the mechanisms underlying rheumatoid arthritis.

LL-37 and Psoriasis

Research suggests that LL-37 may play a role in the pathogenesis of psoriasis. By exploring the interactions between LL-37 and skin disorders, these vials can aid researchers in unraveling the complex dynamics involved in psoriasis, potentially paving the way for innovative therapeutic approaches.

LL-37 and Bacteria

LL-37 has demonstrated antimicrobial activity against a broad spectrum of bacteria. Utilizing LL-37 (CAP-18) Vials in bacterial research can provide insights into the peptide’s efficacy, mechanisms of action, and potential applications for combating bacterial infections.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Cao S, Shi H, Sun G, Chen Y, Hou G, Wang D, Shi B. Serum IL-37 Level Is Associated with Rheumatoid Arthritis and Disease Activity: A Meta-Analysis. Biomed Res Int. 2021 Feb 5;2021:6653439. doi: 10.1155/2021/6653439. PMID: 33628802; PMCID: PMC7884130.. [Read More]
2. Chamorro CI, Weber G, Grönberg A, Pivarcsi A, Ståhle M. The human antimicrobial peptide LL-37 suppresses apoptosis in keratinocytes. J Invest Dermatol. 2009 Apr;129(4):937-44. doi: 10.1038/jid.2008.321. Epub 2008 Oct 16. PMID: 18923446. [Read More]
3. Ridyard KE, Overhage J. The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. Antibiotics (Basel). 2021 May 29;10(6):650. doi: 10.3390/antibiotics10060650. PMID: 34072318; PMCID: PMC8227053. [Read More]